New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
15:02 EDTMDTMedtronic says results from CRYSTAL AF trial met primary endpoint
Medtronic announced results from the CRYSTAL AF Clinical Trial, which found that continuous cardiac monitoring with the Reveal XT Insertable Cardiac Monitor was superior to standard care at detecting atrial fibrillation in patients who have had strokes of undetermined causes. Presented at a late-breaking science session at the American Stroke Association's International Stroke Conference, the randomized, global study met its primary endpoint by demonstrating that continuous monitoring with the Reveal ICM discovered AF in 6.4 times more patients than standard care at six months (p=0.0006). In addition, the Trial found that compared to standard care (including electrocardiograms, Holter monitors and other short-term diagnostic tests prescribed over the follow-up period), the Reveal ICM detected AF in 7.3 times more patients at 12 months (p<0.0001), and 8.8 times more patients at 36 months (p<0.0001). When followed for 36 months, 30 percent of the patients in the ICM arm had AF detected.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
18:02 EDTMDTMedtronic acquires Medina Medical for $150M in cash
Subscribe for More Information
18:01 EDTMDTMedtronic acquires Medina Medical for $150M in cash
14:28 EDTMDTMedtronic volatility elevated into Q1 and outlook
Medtronic September call option implied volatility is at 49, September and October is at 26; compared to its 52-week range of 13 to 38, suggesting large near term price movement into the expected release of Q1 results on September 3.
07:10 EDTMDTMedtronic study detects gene associated with sudden cardiac death
Subscribe for More Information
August 25, 2015
09:07 EDTMDTMedtronic to acquire Twelve for $458M
In support of the company's therapy innovation strategy, Medtronic announced that it has signed a definitive agreement to acquire Twelve, a medical device company focused on the development of a transcatheter mitral valve replacement, or TMVR device. Twelve is the twelfth company spun out from the premier medical device incubator The Foundry. Medtronic has agreed to pay up to $458M for Twelve including $408M at closing and $50M on achievement of CE Marking. The cash- and debt-free transaction remains subject to customary closing conditions, and is expected to close in October 2015.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use